Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

NANOTECH DEFEATS COLON CANCER

Colon cancer – the third most common cancer and the second deadliest – is normally treated with a drug called Capecitabine (CAP), but it’s a shotgun treatment: the drug swarms not only tumors but also healthy tissue, leaving patients with side effects ranging from severe pain in hands and feet to dermatitis to nausea.
Researchers in Australia and India have found a way to zap the tumors and skirt the side effects by loading CAP into designer nanoparticles. 
The particles are made of porous silica with an outer coating that fits key-in-lock fashion onto receptors on tumors’ surfaces. 
Once attached, the CAP moves through the particles’ pores into tumor cells, inflaming them and disrupting their ability to replicate normally.
In rat tests, the treatment produced fewer and milder side effects because the drug dose bypassed most of the healthy tissue but was just as effective in shrinking and killing tumors.
TRENDPOST: The same approach can be applied broadly across other forms of cancer and, once approved by regulators, could subject a range of malignancies to a relatively straightforward cure.

Comments are closed.